Publicly subsidised smoking cessation medicines in times of COVID‐19 in Australia: An interrupted time series analysis
Open Access
- 29 September 2022
- journal article
- research article
- Published by Wiley in Drug and Alcohol Review
- Vol. 42 (1) , 225-232
Abstract
Introduction In Australia, the available published literature demonstrated a spike in dispensed prescription medicines after the onset of the COVID-19 pandemic that subsequently returned to expected levels. Smoking cessation medicines may not follow this pattern because quit attempts are influenced by a range of factors. Knowledge of whether dispensing of these medicines has changed since the pandemic is lacking. We explored the change in dispensing of publicly subsidised smoking cessation medicines since the pandemic. Methods Australia's universal health-care system provides access to government-subsidised medicines via the Pharmaceutical Benefits Scheme and records of dispensed medicines are publicly available on a nationally aggregated level. We retrieved Pharmaceutical Benefits Scheme data from January 2016 to January 2021. We used interrupted time series modelling to quantify the impact of COVID-19 on dispensing of nicotine replacement therapy (NRT) patches, varenicline and all smoking cessation treatments combined separately. Results After an initial spike in medicines at the onset of the pandemic, the monthly rate of prescriptions dispensed for varenicline was predominantly within predicted ranges, while that of NRT patches was predominantly below predicted ranges. Discussion and Conclusions There has been a differential change in the number of subsidised smoking cessation medicines supplied in Australia since the COVID-19 pandemic, with varenicline prescriptions largely within, and NRT patches largely lower than, expected ranges. The reasons for the apparent change in dispensing of subsidised smoking cessation medicines are unclear.Keywords
This publication has 5 references indexed in Scilit:
- Toilet Paper, Minced Meat and Diabetes Medicines: Australian Panic Buying Induced by COVID-19International Journal of Environmental Research and Public Health, 2021
- Smokers’ cognitive and behavioural reactions during the early phase of the COVID-19 pandemic: Findings from the 2020 ITC Four Country Smoking and Vaping SurveyPLOS ONE, 2021
- Increased dispensing of prescription medications in Australia early in the COVID‐19 pandemicMedical Journal of Australia, 2021
- Changes in Tobacco Use During the 2020 COVID-19 Lockdown in New ZealandNicotine & Tobacco Research, 2021
- Tobacco dependence treatment in Australia – an untapped opportunity for reducing the smoking burdenPublic Health Research and Practice, 2020